Business Context and Reporting Period
Company: Can-Fite Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of July 2026
Date of Filing: July 20, 2026
The filing serves to distribute a press release regarding the acceptance of positive Phase 2a pancreatic cancer study data for presentation at the ESMO Congress 2026.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements.
Material Changes
No financial material changes versus the prior comparable period are reported in this document. The primary material event is the scientific milestone regarding the Phase 2a study data acceptance.
Guidance, Outlook, and Management Commentary
- Scientific Milestone: Positive Phase 2a pancreatic cancer study data has been accepted for presentation at the ESMO Congress 2026.
- Event Significance: ESMO Congress is described as one of the world's premier scientific meetings in oncology.
- Management Commentary: The filing does not contain specific management commentary, financial guidance, or risk factors beyond the context of the press release.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for specific clinical trial data details.
- Confirm the schedule and location of the ESMO Congress 2026 presentation.
- Review subsequent filings for any financial impact or operational updates resulting from the study data.